SEOUL, South Korea, April 23, 2024 /PRNewswire/ -- Hanmi Pharmaceutical (KOSPI: 128940, CEO: Jae-Hyun Park), a leading biopharma company in Korea that focuses on research areas such as oncology, obesity/metabolism, and rare diseases, announced it has entered into a Clinical Trial Collaboration and Supply Agreement (CTCSA) with MSD (a tradename of Merck & Co., Inc., Rahway, NJ, USA).
SEOUL, South Korea, March 17, 2023 /PRNewswire/ -- Hanmi Pharmaceuticals (128940.KS), a subsidiary of Hanmi Science (008930.KS) in Korea, announced that the results of large-scale clinical trial with Rosuzet have been published in 'The Lancet' and the 'European Heart Journal'.
Spectrum Pharmaceuticals, Hanmi Pharmaceutical’s U.S. partner, said on Friday that it received a Complete Response Letter (CRL) from the FDA stating that the regulator needs supplementary data to approve poziotinib, a lung cancer treatment.
Hanmi Pharmaceutical said it would begin a local phase 3 trial of poziotinib to treat a certain type of non-small cell lung cancer (NSCLC). Attention is on whether the drugmaker will complete the confirmatory trial, a condition required by the U.S. FDA to obtain marketing approval.
Korea’s Hamni identified silymarin, an extract from traditional liver condition treatment milk thistle, as a way to support hepatic function. However, the crude silymarin extract is lipophilic and poorly soluble in water. Other researchers have found 20% to 50% of the extract is absorbed by the gastrointestinal tract after ingestion, leading multiple groups to work to improve bioavailability.
On Wednesday, Hanmi Pharmaceutical issued the “2021-22 CSR Report” to explain the company’s sustainability management goals and achievements based on Global Reporting Initiative (GRI) Standards, an international guideline for sustainability reporting.
Hanmi Fine Chemical, a subsidiary of Hanmi Pharmaceutical Group specializing in active pharmaceutical ingredients (APIs) development and manufacturing, is expanding its services from APIs to “high-tech” contract development and manufacturing organization (CDMO) services.
Korean pharmaceutical companies, including Hanmi Pharmaceutical, LG Chem, and Yuhan Corp., are accelerating efforts to develop a new obesity drug with a new mechanism of action, a report said.
SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active Pharmaceutical Ingredient) development and manufacturing, is now accelerating a new business, expanding its specialties from ongoing APIs to 'high-tech CDMO' services.
Hanmi Pharmaceutical said that Aptose Biosciences, its American partner, has received orphan drug designation (ODD) for HM43239, an acute myeloid leukemia (AML) treatment, from the U.S. Food and Drug Administration.